GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

It is important for vulnerable people and the elderly to stay up to date on vaccinations such as influenza (to protect ...

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

Melbourne, Australia The Government has expanded access to GSK's shingles vaccine, Shingrix, to cover individuals aged 18 ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

Shingrix is approved to prevent shingles (herpes zoster) in adults aged 50 and older ... Also Read: GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

Aussies who are classified as 'moderate to high risk' and are aged between 18 and 64 now qualify for the immunisation.

About one in three people will develop shingles in their lifetime and nearly all adults aged 50 years and older carry the inactive virus that causes it. But the the risk of develo ...

However, the current rate of adult vaccination in India is minuscule due to which millions of individuals remain vulnerable ...